CAS: 522-40-7; (E)-Hex-3-Ene-3,4-Diylbis(4,1-Phenylene) Bis(Dihydrogen Phosphate)
该化合物是一种磷酸盐-功能化有机化合物,其内核是含有同芳香团的丙烯核心,其结构将反应性烷基桥与两种苯磷酸酯基质结合,使它成为聚合,交叉连接或表面改变应用的多种中间体.二氢磷酸酯组的存在会提高极地溶剂的溶解性,并有助于进一步的化学衍生.这种化合物在材料科学中特别有用,有助于将阻燃聚合物,粘合剂或因其磷含量而涂层合成.其硬而灵活的骨架有助于热稳定性,而不饱和的骨架则有助于光化学或催化工艺的受控再活动.
- 英文名称(E)-Hex-3-Ene-3,4-Diylbis(4,1-Phenylene) Bis(Dihydrogen Phosphate)
- 中文名称乙烯雌酚二磷酸酯
- IUPAC名称(E)-4-(4-(4-(phosphonooxy)phenyl)hex-3-en-3-yl)phenyl dihydrogen phosphate
- 其它别名Fosfestrol; Diethylstilboestroldiphosphate; Alpha,Alpha'-Diethyl-(E)-4,4'-Stilbenediol Bis(Dihydrogen Phosphate); Alpha,Alpha'-Diethyl-, Bis(Dihydrogen Phosphate), (E)-4'-Stilbenediol; Diethylstilbesterol Diphosphate; 3-Hexene-3,4-Diylbis(4,1-Phenylene) Bis[dihydrogen (Phosphate)]; (E)-Hex-3-Ene-3,4-Diylbis(4,1-Phenylene) Bis(Dihydrogen Phosphate); [4-[(E)-4-(4-Phosphonooxyphenyl)Hex-3-En-3-Yl]Phenyl] Dihydrogen Phosphate
- CAS编号522-40-7
- MFCD编号:MFCD00867397
- EINECS号:208-328-8
- FDA UNII编号:A0E0NMA80F
- 分子式:C18H22O8P2分子量:428.31
- 产品CID: 1512974
- 产品分类有机原料 → 苯丙烷和聚酮 → 二苯乙烯类
物理性质
MSDS等安全信息
上下游产品
己烯雌酚 Diethylstilbestrol 56-53-1合成工艺路线路线简述
📜己烯雌酚置于吡啶,三氯氧磷体系中,化学反应生成 乙烯雌酚二磷酸酯
参考文献:Method Of Preparing Sodium Salts Of Diethylstilbestrol Diphosphate
标题:Method Of Preparing Sodium Salts Of Diethylstilbestrol Diphosphate
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902500000-苯乙烯
2902600000-乙苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人：WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
专利号:US-12054512-B2
优先权日:2017-11-10
标 题 :Sting modulator compounds, and methods of making and using
发明人：VYSKOCIL STEPAN; CIAVARRI JEFFREY; CULLIS COURTNEY; ENGLAND DYLAN BRADLEY; GOULD ALEXANDRA E; GREENSPAN PAUL; HU YONGBO; LANGSTON STEVEN; LI GANG; MIZUTANI HIROTAKE; OKANIWA MASANORI
权利人:TAKEDA PHARMACEUTICALS CO
摘要:The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases.The present disclosure relates to a compound represented by the Formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
专利号:US-2023192682-A1
优先权日:2019-11-14
标题:Improved synthesis of kras g12c inhibitor compound
专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Drugs in Japan, -(435), 1990
参考文献:10.1111/j.1442-2042.1996.tb00566.x
摘要:Yoshimura K, Fukui I, Ishikawa Y, Maeda H, Yamauchi T, Kawai T. Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor. Int J Urol. 1996 Sep;3(5):406–7. doi: 10.1111/j.1442-2042.1996.tb00566.x.
参考文献:10.1111/j.1442-2042.2006.01345.x
摘要:Wakisaka M, Nomura K. Clinical experience of hormone therapy to bone metastatic prostate cancer. Int J Urol. 2006 May;13(5):550–4. doi: 10.1111/j.1442-2042.2006.01345.x.
摘要:CAROW R. [Experiences with ST 52-ASTA in the treatment of carcinoma of the prostate]. Z Urol. 1954;47(2):81–93.
参考文献:10.1002/pros.2990240203
摘要:Droz JP, De Smedt E, Kattan J, Keuppens F, Khoury S, Mahler C, Denis L. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate. 1994;24(2):62–6. doi: 10.1002/pros.2990240203.
📝 需求与反馈
尽可能描述清楚需求与问题信息
